Our response to the NICE Early Value Assessment:
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway
Skin cancer generates the most urgent referrals of any cancer in the UK and referrals are growing by over 10% year on year [1]. At the same time, 1 in 4 Consultant Dermatologist posts remain unfilled [2]. Despite sustained and considerable effort from dermatology departments, this has led to waitlists growing significantly. In 2023 >180,000 patients waited more than 28 days after urgent cancer referral for their diagnosis [1], while provisional NHS data suggests that as of September 2024, around 450,000 patients are waiting on Referral to Treatment pathways, with 49% of dermatology patients waiting more than 18 weeks, amounting to 184,000 patients [3].
Skin Analytics’ UKCA marked Class IIa AI as a Medical Device (AIaMD), DERM (Deep Ensemble for the Recognition of Malignancy), is built around our custom built teledermatology platform to help triage patients into the right place, at the right time and to conserve dermatologist capacity for patients who need it.
DERM routed 20-50% of patients to discharge, appropriately ruling out skin cancer 99.8% of the time [4], allowing dermatologists to focus on the patients that need them most.
Skin Analytics and the NHS launched the world’s first AI skin cancer pathway in 2020 as well as the first patient autonomously assessed by AI
Our latest quarterly report showed
DERM has identified up to
Skin Analytics has helped Secondary Care organisations avoid up to
Since 2020, Skin Analytics has launched 24 partnerships using DERM with the NHS
If you would like to know more about how Skin Analytics can help you and your dermatology team deliver best in class dermatology, get in touch.
